Project Grant RF1AG041705

The Department of Health and Human Services Administration for Community Living awarded a $1M Cooperative Agreement under the Alzheimer's Disease Program Initiative (ADPI) (CFDA 93.470) to Opica Adult Day Program & Counseling Center, Inc. in California. The purpose of the ADPI program is to develop and expand the availability of dementia-capable supports and services for persons with Alzheimer's disease and related dementias at the state and community levels. Through this 3-year award from...

The Department of Health and Human Services, Administration for Community Living, awarded a $1,000,000 Alzheimer's Disease Program Initiative (ADPI) Cooperative Agreement to Alzheimers Greater Los Angeles on September 1, 2024. The grant, which runs through August 31, 2027, aims to develop and expand dementia-capable home and community-based services to support individuals with Alzheimer's disease and related dementias (ADRD) and their caregivers in Los Angeles County. The funding will enable...

This $9,082,796 project grant was awarded by the National Institute on Aging (NIA) under the Aging Research (CFDA 93.866) federal grant program. The grant will fund a two-part clinical trial to be conducted by Banner Health's Banner Research Institute in Phoenix, AZ. The trial will evaluate the efficacy of a plaque-clearing antibody (PCA) treatment and a gamma secretase modulator (GSM) treatment, either alone or in combination, in reducing brain amyloid levels and slowing disease progression...

The Department of Health and Human Services Administration for Community Living awarded a $1,000,000 cooperative agreement to Alzheimers Greater LOS Angeles under the Alzheimer's Disease Program Initiative (ADPI) from July 1, 2021 to June 30, 2024. The purpose of the ADPI program is to develop and expand dementia-capable supports and services for persons with Alzheimer's disease and related dementias at the state and community levels. Under this award, Alzheimers Greater LOS Angeles will work to...

This Cooperative Agreement award, valued at $3,474,488.00 and issued by the National Institute on Aging (CFDA 93.866 - Aging Research), supports the development of a small-molecule EP2 receptor antagonist to treat Alzheimer's disease. The primary awardee, Emory University, is leading efforts to define the pharmacokinetic and pharmacodynamic relationships of the lead EP2 antagonist candidates on Alzheimer's pathology markers in mouse models, as well as conducting additional IND-enabling drug...

This federal Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) to The Trustees of Columbia University in the City of New York provides $452,375 to investigate the potential use of the APLP1 protein as an early biomarker for Alzheimer's disease in individuals with Down syndrome. The project aims to leverage recent findings linking endosomal trafficking defects to the early pathology of Alzheimer's disease, which is observed decades before classical...

The Indiana University Microphysiological Systems to Advance Precision Medicine for AD/ADRD (IUMAP-AD) Center has been awarded a $3,335,016 Cooperative Agreement under the National Institute on Aging's (NIA) Aging Research program (CFDA 93.866). The goal of this 5-year project is to develop reproducible, scalable, and standardized 3D brain organoid-based microphysiological systems (MPS) models that recapitulate key features of human Alzheimer's disease (AD) and Alzheimer's disease related...

The Center For Excellence In Aging & Geriatric Health was awarded a $999,623.00 Cooperative Agreement by the U.S. Department of Health and Human Services Administration for Community Living under the Alzheimer's Disease Program Initiative (ADPI) (CFDA 93.470). The purpose of the 3-year project is to develop and expand the availability of dementia-capable supports and services for persons with Alzheimer's disease and related dementias. Specifically, the project will focus on developing a...

This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $454,271 to Florida Atlantic University to investigate the role of amyloid precursor protein (APP) and cholesterol homeostasis in synaptic dysfunction and neurodegeneration related to Alzheimer's disease (AD). The research aims to use human neurons derived from induced pluripotent stem cells (hiNs) to systematically study how mutations affecting APP distribution, trafficking, and interaction...

This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $479,375 to Florida International University to investigate the effects of a small molecule activator of autophagy, TPI-132, on insulin signaling, senescence, and neuropathology in mouse models of Alzheimer's disease. The research aims to develop and test TPI-132 analogs that can more effectively cross the blood-brain barrier and modulate autophagy activity to increase neuroprotection,...